Dealmaking Quarterly Statistics, Q2 2022
A Look At M&A And Alliance Activity Across The Biopharma, Medical Device And In Vitro Diagnostics Industries, April-June 2022
During Q2, biopharma merger and acquisition value reached $25.4bn and drew in $27.3bn in potential deal value from alliances. Device company M&A values reached $2.7bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $534.3m.
You may also be interested in...
Mayne Pharma CEO Steps Down Amid $475m Metrics Contract Services Sale
Significant change is brewing at Mayne Pharma, with the Australian firm announcing the proposed sale of its US-based CDMO business for nearly half-a-billion dollars. At the same time, long time CEO Scott Richards is heading for the exit door.
Chinese Biotechs Partner Up 18.2-Targeting ADCs Amid Intense Domestic Competition
Following rapid R&D growth in the area, China now has roughly 40 drug candidates targeting Claudin 18.2 across various modalities including monoclonal antibodies, antibody-drug conjugates and bispecific antibodies, with a number of contenders now striking international licensing-out deals in a bid to get ahead of rivals.
NewAmsterdam Is Behind Another Try At CETP Inhibition, With Menarini’s Help
Years after failures by Merck, Lilly, Pfizer and Roche, NewAmsterdam hopes to bring a CETP inhibitor to market to lower cholesterol, and signs on with Menarini to lead commercial efforts in Europe.